Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Xilio Therapeutics, Inc.NASDAQ: XLO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $12.65M rose 331.7% year over year, behind the +476.7% change in trailing-twelve-month revenue. Sequentially, it fell 7.6% from the prior quarter.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $42.67M (-2.5%) for the fiscal year ending Dec 2026, a slowdown from the +589.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.65M-7.6% QoQ
Last fiscal yearDec 2025
$43.77M+589.9% YoY
LTMMar 2026
$53.48M+476.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+331.7%+57.3%-274.3 pp
1 year+589.9%-2.5%-592.4 pp
3-year CAGR—-45.2%—
5-year CAGR-35.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
43.77M USD
Year-over-year change
+589.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 revenue of $53.48M is the highest of the 4 companies compared; the peer median is $0.
XLO Competitors Peer median
Revenue for XLO and competitors
Company Period LTM YoY 3-year CAGR
XLOXilio Therapeutics, Inc.LTM Mar 2026$53.48M +476.7%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$35.09M —-55.6%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$0 ——
PDSBPDS Biotechnology CorporationLTM Mar 2026$0 ——
Peer median (excluding XLO) $0—-55.6%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0006.34M43.77M
Cost of Revenue1.5M0001.54M
Gross Profit(1.5M)006.34M42.23M
Gross Margin———100.0%96.5%
Research & Development51.19M59.2M52.14M41.21M56.04M
Selling, General & Admin22.36M29.95M27M24.78M29.71M
Operating Expenses73.55M89.15M79.13M66.93M84.21M
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
EBITDA(73.7M)(86.38M)(74.5M)(58M)(33.5M)
EBITDA Margin———-914.3%-76.5%
Operating Income(75.04M)(89.15M)(79.13M)(60.58M)(41.98M)
Operating Margin———-954.9%-95.9%
Interest Income6000003.4M
Interest Expense600K00100K0
Other Income / Expenses(756K)927K2.73M2.34M6.95M
Income Before Tax(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Pre-Tax Margin———-918.0%-80.1%
Income Tax Expense00000
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Net Margin———-918.0%-80.1%
EPS (Basic)(189.28)(45.08)(38.92)(15.26)(4.19)
EPS (Diluted)(189.28)(45.08)(38.92)(15.26)(4.19)
Weighted Avg Shares400.45K1.96M1.96M3.82M83.59M
Weighted Avg Shares (Diluted)400.45K1.96M1.96M3.82M83.59M

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.